MMP-3-1171 5A/6A Promoter Polymorphism and Cancer Susceptibility: An Updated Meta-Analysis and Trial Sequential Analysis - supplementary material

Supplementary material 1: Figures S1-S6Fig. S1: Forest plot indicating the association of MMP-3-1171 (5A/6A) polymorphism with overall cancer susceptibility in the different genetic models.Fig. 2: Sensitivity plot for detecting the association of MMP-3-1171 (5A/6A) polymorphism and overall cancer risk.Fig. S3: Funnel plots indicating the publication bias for detecting the association of MMP-3-1171 (5A/6A) polymorphism with the overall cancer susceptibilityFig. S4: Trial sequential analysis for MMP-3-1171 (5A/6A) in allele model of the overall meta-analysis.Fig. S5: Box plots of MMP-3 gene expression between tumor and normal tissue in ten cancer types using GEPIA2 web server ((*p ≤ 0.05); T: Tumor tissues; N: Normal tissues; BRCA: Breast invasive carcinoma; ESCA: Esophageal carcinoma; STAD: Stomach adenocarcinoma; COAD: Colon adenocarcinoma; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; OV: Ovarian serous cystadenocarcinoma; HNSC: Head and Neck squamous cell carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; LIHC: Liver hepatocellular carcinoma)).Fig. S6: Impact of MMP3 expression level on the survival of different types of cancer patients generated from UALCAN database ( https://ualcan.path.uab.edu/analysis.html )Table S1: Genotype and data information of the selected studies for meta-analysis to detect the association of MMP-3 ‑1171 5A/6A with cancer riskTable S2. Quality assessment of the included studies by NOS